Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)GlobeNewsWire • 10/10/23
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/19/23
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)Zacks Investment Research • 09/08/23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/07/23
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic AtrophyGlobeNewsWire • 07/30/23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical OfficerGlobeNewsWire • 07/27/23
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023GlobeNewsWire • 07/24/23
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual FunctionGlobeNewsWire • 05/24/23
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 05/21/23
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 05/14/23
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline ProgressGlobeNewsWire • 05/08/23
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 04/23/23
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/11/23
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated MilestonesGlobeNewsWire • 03/06/23
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare ConferenceGlobeNewsWire • 02/27/23
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic FranchisesGlobeNewsWire • 01/08/23
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused PortfolioGlobeNewsWire • 01/06/23
Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a BetZacks Investment Research • 12/01/22
How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246%Zacks Investment Research • 11/15/22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023GlobeNewsWire • 11/03/22